|
06 Jan 2022 |
POLARISqb and PhoreMost announce a multi-target collaboration to investigate next-generation cancer therapies
|
|
06 Jan 2022 |
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
|
|
06 Jan 2022 |
FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
|
|
06 Jan 2022 |
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
|
|
06 Jan 2022 |
Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
|
|
05 Jan 2022 |
Rain Therapeutics and Roche to Collaborate on Clinical Trial of Milademetan Combination with Anti-PD-L1 Immunotherapy for Various Solid Tumor Indications
|
|
05 Jan 2022 |
Leiden University Medical Center and Intravacc to Start Clinical Trial with New Intranasal Corona Vaccine
|
|
05 Jan 2022 |
Allena Pharmaceuticals Provides Clinical and Corporate Update
|
|
05 Jan 2022 |
Gritstone Announces Positive Clinical Results from First Cohort of a Phase 1 Study (CORAL-BOOST) Evaluating a T Cell-Enhanced Self-Amplifying mRNA (samRNA) Vaccine Against COVID-19
|
|
05 Jan 2022 |
Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration
|
|
05 Jan 2022 |
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Trial of RLY-2608 and Initiation of Expansion Cohorts for First-In-Human Trial of RLY-4008
|
|
05 Jan 2022 |
Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data
|
|
05 Jan 2022 |
Dystrogen Therapeutics Announces First in Man Dosing of Novel Chimeric Cell Therapy for Duchenne Muscular Dystrophy and Reports 6-week Clinical Outcomes
|
|
05 Jan 2022 |
AVROBIO Reprioritizes Pipeline Programs
|
|
05 Jan 2022 |
Amylyx Pharmaceuticals Submits Marketing Authorization Application (MAA) for AMX0035 for the Treatment of ALS
|
|
05 Jan 2022 |
Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Monoclonal Antibody
|
|
05 Jan 2022 |
NewAmsterdam Pharma Doses First Patient in Phase 3 BROADWAY Trial of Obicetrapib in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) and/or Established Atherosclerotic Cardiovascular Disease (ASCVD)
|
|
05 Jan 2022 |
OrphoMed, Inc. Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose in IBS-D Patients
|
|
05 Jan 2022 |
Genmab and Synaffix Enter into License Agreement for ADC Technology
|
|
05 Jan 2022 |
AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer
|
